Cambridge, United Kingdom – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
With the In Vitro Diagnostic (IVD) designation, Congenica’s clinical decision support platform can make the transition from research to clinical use and be applied to the clinical diagnosis of patients with rare hereditary genomic disorders. The platform is the only CE marked IVD software for genomic diagnostics…
Increasing numbers of employees are being asked to self-isolate after being exposed to COVID, putting pressure on employers.
Employment lawyer, and Partner, Helen Farr was featured on BBC Radio 5 Live.
Click the link to listen.
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
The initial phase of the expansion will see the installation of two 2,000-liter single-use…
20 July 2021: Future Fund: Breakthrough, announced by the Chancellor of the Exchequer at Budget 2021, opens today for applications. This UK-wide programme will deliver £375m of government funding via British Patient Capital, a commercial subsidiary of the British Business Bank.
Due to high research and development costs, breakthrough technology companies typically require more capital than other companies, to fuel the later stages of their growth. Because of their ability to grow rapidly and have a significant economic impact, the growth of these innovative companies is critical to the UK’s…
NHS patients are set to benefit from early access to potentially life-saving new medicines, including cutting-edge gene therapies, thanks to a new Innovative Medicines Fund and £680 million of ringfenced funding, the NHS chief executive has announced today.
The Innovative Medicines Fund (IMF) will build upon the success of the reformed Cancer Drugs Fund (CDF), by supporting patients with any condition, including those with rare and genetic diseases, to get early access to the most clinically promising treatments where further data is needed to support NICE in making final recommendations…
Cambridge, UK: 20 July 2021
One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge, exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes promoting and leveraging the world class excellence within our network and beyond, by facilitating the right connections.
Now it has joined with eight other high profile and strategic business clusters – including the Silverstone Technology Cluster (STC) – to work together to explore ways to connect high-tech businesses,…
We will not let hate suppress the success of others. We want to recognise the incredible achievements of the England #football team, and the hard work and strength they've inspired. They should be celebrated.
Everyone, whatever your profession, should have the support and freedom to excel.
We condemn the vicious and racist abuse of all professionals, whether that's online or otherwise, and stand in solidarity with other organisations and leaders who empower success unconditionally.
Today we announce our results for the financial year to 30 April 2021.
The firm has seen a 12% increase in UK revenue to £175.5m and a 23% increase in UK profit to £71m. UK profit per equity partner is 18% up on last year.
UK Managing Partner, Shane Gleghorn, said: "Our focus this financial year has been our people and clients, and these pleasing results are attributable to their commitment to the firm. We anticipated, and had, a slow start to our financial year due to the contraction caused by the onset of the pandemic. We were confident, however, that the focus of our sector and…
Cambridge, UK, 15 July 2021 – PharmEnable, an AI drug discovery company unlocking challenging biological targets, announces that it has entered into a drug discovery collaboration with LifeArc, an independent UK medical research charity, to apply their respective technologies and expertise to discover novel oral antiviral drugs with activity against coronaviruses.
The COVID-19 pandemic has not only demonstrated the threat that novel and variant viruses pose, but also the vital role of innovative science to develop vaccines and drugs to combat infection, improving patient health while…
AMSBIO has established an unmatched commercial biorepository and procurement network that includes a large selection of fully characterized and annotated Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks to help streamline your research.Drawing upon decades of experience - AMSBIO is able to offer an extensive collection of frozen and paraffin-embedded (FFPE) human and animal tissue samples from normal and many diseased tissue types. All FFPE tissue blocks are processed using standard clinical procedures, under Institutional Review Board (IRB) approved protocols. Each tissue…